Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Strati

Showing results (71-80 of 139) with videos related to

Pageof 14
Sort By:
Ejhaem|September 1, 2020
Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?Jillian R Gunther, Chelsea C Pinnix, Gordon R Glober, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2017
Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOPPaolo Strati, Nathan Fowler, Sergio Pina-Oviedo, et al.
Blood Advances|May 12, 2019
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLLPaolo Strati, Koichi Takahashi, Christine B Peterson, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2020
A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) LymphomaPenny Fang, Jillian R Gunther, Chelsea C Pinnix, et al.
Lancet (London, England)|January 11, 2025
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trialArmin Ghobadi, Veronika Bachanova, Krish Patel, et al.
Eclinicalmedicine|August 20, 2024
Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trialAshwath Gurumurthi, Collin K Chin, Lei Feng, et al.
Practical Radiation Oncology|July 10, 2026
Safety of concurrent radiation therapy with the antibody-drug conjugate polatuzumab vedotin in relapsed or refractory aggressive B-cell lymphomasSophie T Melancon, Ethan B Wang, Penny Q Fang, et al.
Leukemia & Lymphoma|November 10, 2017
Myeloid/lymphoid neoplasms with FGFR1 rearrangementPaolo Strati, Guilin Tang, Dzifa Y Duose, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
Cancer|April 9, 2026
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025Alexey V Danilov, Catherine C Coombs, Tycel Phillips, et al.
Pageof 14

Showing results (71-80 of 139) with videos related to

Sort By:
Pageof 14
Ejhaem|September 1, 2020
Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?Jillian R Gunther, Chelsea C Pinnix, Gordon R Glober, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2017
Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOPPaolo Strati, Nathan Fowler, Sergio Pina-Oviedo, et al.
Blood Advances|May 12, 2019
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLLPaolo Strati, Koichi Takahashi, Christine B Peterson, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2020
A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) LymphomaPenny Fang, Jillian R Gunther, Chelsea C Pinnix, et al.
Lancet (London, England)|January 11, 2025
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trialArmin Ghobadi, Veronika Bachanova, Krish Patel, et al.
Eclinicalmedicine|August 20, 2024
Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trialAshwath Gurumurthi, Collin K Chin, Lei Feng, et al.
Practical Radiation Oncology|July 10, 2026
Safety of concurrent radiation therapy with the antibody-drug conjugate polatuzumab vedotin in relapsed or refractory aggressive B-cell lymphomasSophie T Melancon, Ethan B Wang, Penny Q Fang, et al.
Leukemia & Lymphoma|November 10, 2017
Myeloid/lymphoid neoplasms with FGFR1 rearrangementPaolo Strati, Guilin Tang, Dzifa Y Duose, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
Cancer|April 9, 2026
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025Alexey V Danilov, Catherine C Coombs, Tycel Phillips, et al.
Pageof 14